{
    "root": "3468f697-9ecf-ac82-e063-6394a90a398e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Glipizide",
    "value": "20250505",
    "ingredients": [
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "POLYETHYLENE OXIDE 200000",
            "code": "11628IH70O"
        },
        {
            "name": "POLYETHYLENE OXIDE 7000000",
            "code": "G3MS6M810Y"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "CELLULOSE ACETATE",
            "code": "3J2P07GVB6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "GLIPIZIDE",
            "code": "X7WDT95N5C"
        }
    ],
    "indications": "Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications": "Recommended starting dose is 5 mg once daily. Dose adjustment can be made based on the patient’s glycemic control. Maximum recommended dose is 20 mg once daily ( 2.1 ). Administer with breakfast or the first meal of the day ( 2.1 ). For combination therapy with other blood-glucose-lowering agents, initiate the agent at the lowest recommended dose, and observe patients for hypoglycemia ( 2.2 ).",
    "warningsAndPrecautions": "Glipizide extended-release tablets are supplied to provide 5 mg round, biconvex tablets and imprinted with black ink as follows:\n                  White Round Biconvex, imprinted with “P ” on one side 5 on the other side.\n                  \n                  NDC: 70518-1063-00\n                  NDC: 70518-1063-01\n                  NDC: 70518-1063-02\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Recommended Storage: The tablets should be protected from moisture and humidity. Store at 20° to 25°C (68° to 77º F); [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions": "Glipizide is contraindicated in patients with:\n                  \n                     Known hypersensitivity to glipizide or any of the product’s ingredients.\n                     Hypersensitivity to sulfonamide derivatives."
}